Role of induction chemotherapy in advanced‐stage olfactory neuroblastoma
International Forum of Allergy & Rhinology · 2024
DOI: 10.1002/alr.23428 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2024. Verfasst von Sung-Woo Cho und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Seongnam, South Korea. Hauptthemen laut MEDLINE: Esthesioneuroblastoma, Olfactory, Induction Chemotherapy, Nose Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
To evaluate the treatment outcomes in patients with advanced‐stage olfactory neuroblastoma (ONB) who received induction chemotherapy (IC). Materials and methods The clinical data of 38 patients with advanced‐stage ONB who received initial IC were retrospectively analyzed. The response was defined using the Response Evaluation Criteria in Solid Tumors version 1.1. Patients with complete remission or partial remission were defined as responders.
Results
Seventeen (44.7%) patients responded to IC. The response rate was higher in patients with high Hyams grade tumor (III/IV) compared to those with low‐grade tumors (I/II) (60% vs. 22.2%, p = 0.038). Overall, the 5‐year cancer‐specific survival (CSS) rate was 76.0%. Among nonresponders to IC, a significant difference in 5‐year CSS rates was observed between surgery with adjuvant radiotherapy (RT) (100%) versus definitive RT or chemoradiotherapy (CRT) (68.6%) (log‐rank p = 0.006). However, for responders, there was no significant difference in 5‐year CSS rates between surgery with adjuvant therapy (75%) and definitive RT or CRT (51.1%) (log‐rank p = 0.536). When only high‐grade tumors were considered among responders, the 5‐year CSS rate was significantly higher in patients who received RT or CRT (51.4%) compared to those who underwent surgery with adjuvant therapy (0%) (log‐rank p = 0.008).
Conclusion
In advanced‐stage ONB, RT or CRT may be preferable for high‐grade tumor responding to IC. Higher response rate and a potential role for induction IC in determining the optimal definitive treatment modality suggest a positive role for advanced‐stage high‐grade ONB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Seongnam, South Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
- Department of Otorhinolaryngology, Head and Neck Surgery, Seoul National University Hospital, Seoul, South Korea.
- Sensory Organ Research Institute, Seoul National University Medical Research Center, Seoul, South Korea.
- Department of Radiology, Seoul National University Bundang Hospital, Seongnam, South Korea.
ORCID-Profile: Sung-Woo Cho
Förderung
- National Research Foundation of Korea
Zitieren
APA
Cho, S. W., Keam, B., Lee, K. W., Kim, J. W., Han, D. H., Kim, H. J., Kim, J. W., Kim, D. Y., Rhee, C. S., Bae, Y. J., Kim, J. H., Eom, K. Y., Wu, H. G., Kim, Y. H., Kim, C. Y., Paek, S. H., Kim, H., & Won, T. B. (2024). Role of induction chemotherapy in advanced‐stage olfactory neuroblastoma. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23428
Vancouver
Cho SW, Keam B, Lee KW, Kim JW, Han DH, Kim HJ, et al. Role of induction chemotherapy in advanced‐stage olfactory neuroblastoma. International Forum of Allergy & Rhinology. 2024. doi:10.1002/alr.23428
BibTeX
@article{Cho2024,
author = {Cho, Sung-Woo and Keam, Bhumsuk and Lee, Keun-Wook and Kim, Ji-Won and Han, Doo Hee and Kim, Hyun Jik and Kim, Jeong-Whun and Kim, Dong-Young and Rhee, Chae-Seo and Bae, Yun Jung and Kim, Ji-Hoon and Eom, Keun-Yong and Wu, Hong-Gyun and Kim, Yong Hwy and Kim, Chae-Yong and Paek, Sun Ha and Kim, Hyojin and Won, Tae-Bin},
title = {Role of induction chemotherapy in advanced‐stage olfactory neuroblastoma},
journal = {International Forum of Allergy & Rhinology},
year = {2024},
doi = {10.1002/alr.23428}
}
EUVIMED